tirofiban has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forleo, GB; Radovanovic, D; Santus, P; Viecca, M | 1 |
| Chen, Y; Fu, B; Li, P | 1 |
1 trial(s) available for tirofiban and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.
Topics: Aged; Aspirin; Betacoronavirus; Clopidogrel; Compassionate Use Trials; Coronavirus Infections; COVID-19; Female; Fibrin Fibrinogen Degradation Products; Humans; Hypoxia; Male; Middle Aged; Pandemics; Platelet Aggregation Inhibitors; Pneumonia, Viral; Proof of Concept Study; SARS-CoV-2; Thrombophilia; Tirofiban | 2020 |
1 other study(ies) available for tirofiban and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
2019 novel coronavirus disease with secondary ischemic stroke: two case reports.
Topics: Aspirin; Atorvastatin; Brain Ischemia; COVID-19; Fibrinolytic Agents; Humans; Ischemic Stroke; Male; Middle Aged; Pandemics; SARS-CoV-2; Tirofiban | 2021 |